New molecular marker for prostate cancer
This article was originally published in Clinica
US researchers have discovered a new protein marker for prostate cancer. The marker could help doctors predict whether patients with tumours which have not spread are more likely to die from the disease. Testing for the marker could pick out patients who need aggressive therapy during the early stages of the disease, allowing others to avoid these intensive and expensive treatments.
You may also be interested in...
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.
Biopharma is working on a reputation renaissance as the public looks to industry for treatments and vaccines for the COVID-19 epidemic and drug pricing concerns take a back seat.